Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-04
2005-01-04
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S242000, C424S093200
Reexamination Certificate
active
06838437
ABSTRACT:
The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe3O9 is mutated. The nucleic acid sequences of the present invention also encode amino acid sequences corresponding to known human FVIII sequences, wherein the APC cleavage sites, Arg336 and Ile562, are mutated. The nucleic acid sequences of the present invention further encode amino acid sequences corresponding to known human FVIII sequences, wherein the B-domain is deleted, the von Willebrand factor binding site is deleted, a thrombin cleavage site is mutated and an amino acid sequence spacer is inserted between the A2- and A3-domains. Methods of producing the FVIII proteins of the invention, nucleotide sequences encoding such proteins, pharmaceutical compositions containing the nucleotide sequences or proteins, as well as methods of treating patients suffering from hemophilia, are also provided.
REFERENCES:
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4868112 (1989-09-01), Toole, Jr.
patent: 5004803 (1991-04-01), Kaufman et al.
patent: 5045455 (1991-09-01), Kuo et al.
patent: 5214033 (1993-05-01), Zimmerman et al.
patent: 5250421 (1993-10-01), Kaufman et al.
patent: 5451521 (1995-09-01), Kaufman et al.
patent: 5563045 (1996-10-01), Pittman et al.
patent: 5661008 (1997-08-01), Almstedt et al.
patent: 295597 (1988-12-01), None
patent: 197901 (1991-07-01), None
patent: WO 8704187 (1987-07-01), None
patent: WO 8706101 (1987-10-01), None
patent: WO 8707144 (1987-12-01), None
patent: WO 8803558 (1988-05-01), None
patent: WO 8808035 (1988-10-01), None
patent: WO 9107490 (1991-05-01), None
patent: WO 9703194 (1997-01-01), None
patent: WO 9703195 (1997-01-01), None
patent: WO 9740145 (1997-10-01), None
Marquette, K, Pittman, D, and Kaufman, R. “A 110-amino acid region within the A1-domain of Coagulation Factor VIII inhibits secretion from mammalian cells.” vol. 270, No. 17, pp. 10297-10303, Apr. 28, 1995.*
Pittman, D and Kaufman, R. “Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).” vol. 85, pp. 2429-2433, Apr. 1988.*
Bertina et al. “Mutation in blood coagulation factor V associated with resistance to activated protein C.”Nature.May 5, 1994;369(6475):64-7.
Blond-Elguindi et al. “Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP.”Cell.Nov. 19, 1993;75(4):717-28.
Brinkhous et al. “Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.”PNAS USA.Dec. 1985;82(24):8752-6.
Castaman et al. “Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate.”Am. J. Hematol.Oct. 1992;41(2):132-6.
Cripe et al. “Structure of the gene for human coagulation factor V.”Biochemistry.Apr. 21, 1992;31(15):3777-85.
Dahlbäck et al. “Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.”PNAS USAFeb. 1, 1993;90(3):1004-8.
Dahlbäck et al. “Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.”PNAS USAFeb. 15, 1994;91(4):1396-400.
Davis et al. “The coagulation cascade: initiation, maintenance, and regulation.”Biochemistry.Oct. 29, 1991;30(43):10363-70.
Dorner et al. “The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins.”J. Cell Biol.Dec. 1987;105(6 Pt 1):2665-74.
Dorner et al. “Increased synthesis of secreted proteins induces expression of glucose-regulated proteins in butyrate-treated Chinese hamster ovary cells.”J. Biol. Chem.1989;264(34):20602-7.
Dorner et al. “Protein dissociation from GRP78 and secretion are blocked by depletion of cellular ATP levels.”PNAS USAOct. 1990;87(19):7429-32.
Dorner et al. “Overexpression of GRP78 mitigates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells.”EMBO J.Apr. 1992,11(4):1563-71.
Eaton et al. “Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.”Biochemistry.Jan. 28, 1986;25(2):505-12.
Fay et al. “von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation.”J. Biol. Chem.Feb. 5, 1991;266(4):2172-7.
Fay et al. “Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit.”J. Biol. Chem.May 15, 1991;266(14):8957-62.
Fay et al. “Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity.”J. Biol. Chem.Oct. 25, 1991;266(30):20139-45.
Fay et al. “Role of COOH-terminal acidic region of A1 subunit and in A2 subunit retention in human factor VIIIa.”J. Biol. Chem.Aug. 25, 1993;268(24):17861-6.
Fay et al. “Factor VIIIa A2 subunit residues 558-585 represent a factor IXa interactive site.”J. Biol. Chem.Aug. 12, 1994;269(32):20522-7.
Flynn et al. “Peptide binding and release by proteins implicated as catalysts of protein assembly.”ScienceJul. 28, 1989;245(4916):385-90.
Fulcher et al. “Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.”BloodFeb. 1984;63(2):486-9.
Gitschler et al. “Characterization of the human factor VIII gene.”NatureNov. 22-28, 1984:312(5992):326-30.
Guinto et al. “The complete cDNA sequence of bovine coagulation factor V.”J. Biol. Chem.Feb. 15, 1992;267(5):2971-8.
Healey et al. “Residues Glu2181-Val2243 Contain a Major Determinant of the Inhibitory Epitope in the C2 Domain of Human Factor VIII,”Blood,1998, 92(10):3701-9.
Jenny et al. “Complete cDNA and derived amino acid sequence of human factor V.”PNAS USAJul. 1987;84(14):4846-50.
Kane et al. “Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin.”PNAS USASep. 1986;83(16):6800-4.
Kaufman et al. “Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene.”J. Mol. Biol.Aug. 25, 1982;159(4):601-21.
Kaufman et al. “Identification of the components necessary for adenovirus translational control and their utilization in cDNA expression vectors.”PNAS USAFeb. 1985;82(3):689-93.
Kaufman et al. “Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.”J. Biol. Chem.May 5, 1988;263(13):6352-62.
Kozutsumi et al. “The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins.”NatureMar. 31, 1988;332(6163):462-4.
Koedam et al. “Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect on von Willebrand factor.”J. Clin. Invest.Oct. 1988;82(4):1236-43.
Lenting et al. “Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII.”J. Biol. Chem.Mar. 11, 1994;269(10):7150-5.
Leyte et al. “Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand f
Amano Kagehiro
Kaufman Randal J.
Pipe Steven W.
Carlson Karen Cochrane
Desai Anand
Lahive & Cockfield LLP
Smith, Esq. DeAnn F.
University of Michigan
LandOfFree
Inactivation resistant factor VIII does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inactivation resistant factor VIII, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inactivation resistant factor VIII will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423333